Pulse Revenue Surpasses A$1.1 Million with 200% Quarterly Growth at CONNEQT

Strong Consumer Momentum Drives Revenue Growth

CONNEQT Health has delivered an impressive performance in the December 2025 quarter, with Pulse device sales more than tripling compared to the previous quarter. This surge, surpassing the company’s own AGM expectations, was fuelled by disciplined pricing strategies, targeted marketing, and operational excellence during the peak holiday season. The company’s decision to reduce the Pulse device price to US$249 while introducing in-app purchases and subscription plans has broadened access and sustained demand even after a subsequent price increase to US$289.

The launch of Care+, a subscription service offering ongoing cardiology reports, has been met with encouraging uptake. Over 12% of new customers have subscribed since October, with a strong preference for annual plans and a high retention rate of 92% among monthly subscribers. This early traction signals a promising shift towards recurring consumer revenue streams, complementing device sales.

Enterprise Strategy Advances with Recurring Contracts

On the enterprise front, CONNEQT has successfully transitioned two clinical pilots into multi-year contracts under a consumption-based pricing model. This marks a strategic pivot from one-time capital equipment sales to a scalable, software-enabled revenue approach. While initial contract values are modest, the model opens access to a wider clinical market previously constrained by high upfront costs.

The company’s vascular biomarker technology, centralised in the CONNEQT Cardiology Report, is gaining traction in cardiology and preventive care clinics. The recurring revenue model aligns pricing with actual clinical usage, creating potential for significant account growth over time. Notably, the largest clinical customer currently generates over 13,000 assessments annually, which could translate to substantial recurring revenue under the new model.

Operational Efficiencies and Platform Development

CONNEQT has consolidated its R&D and engineering teams into a single Sydney hub, achieving a 30% reduction in engineering costs and faster product delivery. This operational transformation supports the company’s long-term vision of evolving from a hardware-centric business to a data-driven platform offering arterial health insights.

Future platform enhancements include expanding analytics services for pharmaceutical and research partners, developing Biomarker-as-a-Service capabilities, and introducing new subscription features such as arterial age insights and telehealth support. These initiatives aim to deepen engagement and embed arterial health assessment into routine consumer and clinical workflows.

Financial Position and Outlook

The quarter closed with a strengthened balance sheet following a A$3.1 million institutional placement, including a significant commitment from the company’s largest shareholder. Cash receipts nearly doubled quarter-on-quarter, driven by Pulse and ATCOR sales, while marketing and operational investments increased to support growth initiatives.

Looking ahead, CONNEQT plans to sustain consumer momentum, optimise subscription offerings, and scale enterprise adoption through refined sales and operational processes. The company’s focus remains on expanding recurring revenue streams and embedding its technology more deeply into healthcare settings.